Assessing antibacterial pharmacoeconomics in the intensive care unit

PharmacoEconomics

Volumn 12, Issue 6, 1997, Pages 637-647

  Birmingham, Mary C ^a,b,c   Hassett, James M ^a   Schentag, Jerome J ^a,b   Paladino, Joseph A ^a,b  

^a Millard Fillmore Gates Circle Hospital   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GLYCOPEPTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG DOSE; DRUG USE; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0030670881     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712060-00004     Document Type: Review

References (67)

1. Bone RC. Economic analysis of the intensive care unit: a dilemma [editorial]. Intensive Care Med 1995; 23: 805
2. Sonnefield S, Waldo D, Lemieux L, et al. Projections of national health expendiures through the year 2000. Health Care Financ Rev 1991; 13: 1-27
3. Singer M, Myers S, Hall G, et al. The cost of intensive care: a comparison on one unit between 1988 and 1991. Intensive Care Med 1994; 20: 542-9
4. Durand-Zaleski I. Estimating the cost of intensive care. Intensive Care Med 1994; 20: 538-9
5. Sundrani S. Neuologic intensive care unit management and economic issues. Neurol Clin 1995; 13 (3): 679-93
6. Butler P, Bone R, Field T. Technology under medicare diagnosis-related groups prospective payments: complications for medical intensive care. Chest 1985; 87: 229-34
7. Paladino JA, Fell, RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28: 384-9
8. Leigh DA. Antimicrobial usage in forty-three hospitals in England. J Antimicrob Chemother 1982; 9: 75-84
9. Roder BL, Nielsen SL, Magnussen P, et al. Antibiotic usage in a Danish university hospital. J Antimicrob Chemother 1993; 32: 633-42
10. Dasta JF. Drug use in a surgical intensive care unit. Drug Intell Clin Pharm 1986; 20: 752-6
11. Dasta JF, Jacobi J, Armstrong DK. Role of the pharmacist caring for the critically ill patient. In: Chernow BC, editor. The pharmacologic approach to the critically ill patient. Baltimore: Williams & Wilkins, 1994: 156-66
12. Dasta JF, Armstrong DK. Pharmacoeconomic impact of critically ill surgical patients. Drug Intell Clin Pharm 1988; 22: 994-8
13. Barriere SL. Cost-containment of antimicrobial therapy. Drug Intell Clin Pharm 1985; 19: 278-81
14. Mann HJ, Wittbrodt ET. Identifying drug usage patterns in the intensive care unit. Pharmacoeconomics 1993; 4 (4): 235-9
15. Marschner JP, Thürmann P, Harder S, et al. Drug utilization review on a surgical intensive care unit. Int J Clin Pharmacol Ther 1994; 32 (9): 447-51
16. Crane VS. Pharmacoeconomics: therapeutic and economic considerations in treating the critically ill patient. DICP. Ann Pharmacother 1990 Nov; 24 Suppl. 11: S24-27
17. Davey P. Pharmacoeconomics of appropriate antimicrobial use. Diagn Microbiol Infect Dis 1995; 22: 225-9
18. Moore FD. The role of surgery in national expenditures: what costs are controllable? Ann Surg 1985; 201: 132-41
19. Dunagan WC, Woodward RS, Medoff G, et al. Antibiotic misuse in two clinical situations: positive blood culture and administration of aminoglycosides. Rev Infect Dis 1991; 13: 405-12
20. Gyssens IC, Kullberg BJ. Improving the quality of antimicrobial drug use can result in cost containment. Pharm World Sci 1995; 17 (5): 163-7
21. Rifenburg RP, Paladino JA, Hanson SC, et al. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm 1996; 53: 2054-62
22. Guglielmo BJ. Practical strategies for the appropriate use of antimicrobials. Pharm World Sci 1995; 17 (4): 96-102
23. Koeller JM. Rational use of antibiotics in the critically ill patient. DICP 1990; 24 Suppl. 11: S17-9
24. Schentag JJ, Carr JR, Adelman MH, et al. Formulary management vs. disease management. Infect Dis Clin Pract 1996; 5 Suppl. 1: S42-7
25. Forrest A, Ballow CH, Nix DE, et al. Population pharmacodynamics of ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1073-81
26. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
27. McDonald M, Maloney A, Clarke TA, et al. Blood cultures and antibiotic use in a neonatal intensive care unit. Ir J Med Sci 1992; 161: 3-4
28. Kirton OC, Civetta JM, Hudson-Civetta J. Cost effectiveness in the intensive care unit. Surg Clin North Am 1996; 76 (1): 175-200
29. Moss F, McNicol MW, McSwiggan DA, et al. Survey of antimicrobial prescribing in a district general hospital I: pattern of use. Lancet 1981; II (8242): 349-52
30. Moss F, McNicol MW, McSwiggan DA, et al. Survey of antimicrobial prescribing in a district general hospital II: lower respiratory tract infection. Lancet 1981; II (8242): 407-9
31. Moss F, McNicol MW, McSwiggan DA, et al. Survey of antimicrobial prescribing in a district general hospital III: urinary tract infection. Lancet 1981; II (8242): 461-2
32. Kollef MH. Antibiotic use and antibiotic resistance in the intensive care unit: are we curing or creating disease? Heart Lung 1994; 23 (5): 363-7
33. Berman JR, Zaran FK, Rybak MJ. Pharmacy-based antimicrobial service. Am J Hosp Pharm 1992; 49: 1701-6
34. Schentag JJ. Understanding and managing microbial resistance in institutional settings. Am J Health Syst Pharm 1995; 52 Suppl. 2: S9-14
35. Paladino JA, Sperry H, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin following an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-70
36. Paladino JA, Cumbo TJ, Schentag JJ, et al. Abbreviating the duration of intravenous antibiotics with oral fluoroquinolones [abstract no. 275]. 4th International Symposia on New Quinolones. 1992 Aug 28; Munich, 341
37. Paladino JA. Pharmacoeconomic comparison of ciprofloxacin and ceftazidime. Can J Hosp Pharm 1995; 48: 276-83
38. Carr JR, Fitzpatrick P, Izzo JL, et al. Changing the infection control paradigm from off-line to real-time: the experience at Millard Fillmore Health System. Infect Control Hosp Epidemiol 1997; 18: 255-9
39. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993; 16: 255-64
40. Schentag JJ. The results of a targeted pharmacy intervention program. Clin Ther 1993; 15 Suppl. A: 29-36
41. Felmingham D. Antibiotic resistance: do we need new therapeutic approaches? Chest 1995; 108 (2 Suppl.): 70S-8S
42. Clarke MJ, Paladino JA. Pharmacoeconomic comparison of cefepime vs ceftazidime in septic patients. J Infect Dis Pharmacother 1996; 2: 1-17
43. McKinnon PS, Paladino JA, Grayson ML, et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24: 57-63
44. Dasta JF, Jacob J. The critical care pharmacist: what you get is more than what you see. Crit Care Med 1994; 22 (6): 906-9
45. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. JAMA 1994; 271 (20): 1598-601
46. Kappstein I, Schulgen G, Beyer U, et al. Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit. Eur J Clin Microbiol Infect Dis 1992; 11 (6): 504-8
47. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antimicrobial use. Rev Infect Dis 1983; 5: 1033-48
48. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15 (2 Suppl.): 37S-42S
49. Amsden GW, Ballow CH, Schentag JJ. Rational antimicrobial utilization and resistance issues. Pharmacol Ther 1993; 18: 255-62
50. Kunin CM, Lipton HL, Tupasi TE, et al. Social, behavioral, and practical factors affecting antibiotic use worldwide: report of Task Force 4. Rev Infect Dis 1987; 9 Suppl. 3: S270-85
51. Kunin CM, Johansen KS, Worning AM, et al. Report of a symposium on use and abuse of antibiotics worldwide. Rev Infect Dis 1990; 12: 12-9
52. Leibovici L, Konisberger H, Pitlik SD, et al. Patients at risk for inappropriate antibiotic treatment of bacteremia. J Intern Med 1992; 231: 371-4
53. Wunderink RG. Mortality and ventilator-associated pneumonia: the best antibiotics may be the least antibiotics. Chest 1993; 104: 993-5
54. Holmberg S, Solomon S, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-78
55. Hamilton-Miller JMT. The emergence of antibiotic resistance: myths and facts in clinical practice. Intensive Care Med 1990; 16 Suppl. 3: S206-11
56. Phelps CE. Bug/drug resistance: sometimes less is more. Med Care 1989; 27: 194-203
57. Freeman J, Rosner BA, McGowan JE. Adverse effects of nosocomial infection. J Infect Dis 1979; 140: 732-40
58. Goldman DA, Weinstein, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275: 234-40
59. Kim JH, Gallis HA. Observations on spiraling empiricism: its causes, allure, and perils, with particular reference to antibiotic therapy. Am J Med 1989; 87: 201-6
60. Jackson GG. Antibiotic policies, practices and pressures. J Antimicrob Chemother 1979; 5: 1-4
61. Cunha BA. Intensive care, not intensive antibiotics. Heart Lune 1994; 23 (5): 361-2
62. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimcrob Agents Chemother 1991; 35: 1697-704
63. North D. Controlling the costs of antibiotic resistance. Clin Ther 1993; 15 Suppl. A: 3-11
64. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77 Suppl. 6A: 43S-50S
65. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28 (2): 143-60
66. Schentag JJ, Nix DE, Forrest A, et al. AUIC: the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30: 1029-31
67. Paladino JA, Zimmer GS, Schentag JJ. The economic potential of dual individualisation methodologies. Pharmacoeconomics 1996; 6 (6): 539-545